Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, regulation of AMPK activity may be potentially useful as a therapy for th</span>yroid cancer</span> if the cancer harbors a BRAF V600E mutation.
|
21795305 |
2011 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Investigating BRAF((V600E)) inhibitors (BRAFi) as a strategy to treat patients with aggressive thyroid tumors harboring the BRAF((V600E)) mutant currently is in progress, and drug resistance is expected to pose a challenge.
|
26456124 |
2016 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V600E expression in thyroid cancer.
|
25262966 |
2015 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Notch functions as an oncogene or tumor suppressor according to the type of malignancy, and the BRAF(V600E) mutation is commonly observed in thyroid cancer.
|
22118425 |
2012 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, our study showed a high implication of TSHR gene methylation and its significant association with BRAF V600E mutation in thyroid tumors, depicting a positive connection between TSHR pathway and MAP Kinase pathway.
|
24927793 |
2014 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
It is evident that the detection of the BRAF V600E mutation is crucial in order to identify novel avenues for thyroid cancer treatment.
|
22858857 |
2012 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
After treatment with the potent MEK 1/2 inhibitor AZD6244, MEK inhibition and cell growth were examined in four BRAF mutant (V600E) and two BRAF wild-type thyroid cancer cell lines and in xenografts from a BRAF mutant cell line.
|
17878251 |
2007 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic alterations occurring in thyroid cancer frequently affect the RAS/RAF/MEK/ERK-pathway such as the oncogenic, kinase-activating BRAF(V600E) mutation.
|
26892809 |
2016 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
According to the literature, our data provide evidence of the BRAF and RAS roles in thyroid tumorigenesis, supporting an association between BRAF (V600E) mutations and the more aggressive clinical and pathological features of thyroid tumors.
|
29435002 |
2018 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study investigates the expression of CYP24A1 and the effect of BRAF(V600E) on its expression in thyroid cancer.
|
24382015 |
2014 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that fibroblasts were recruited to the TME of Braf(V600E)/Pten(-/-)/TPO-Cre thyroid tumors.
|
26818109 |
2016 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, somatic p.V600E BRAF mutations were also detected in the thyroid tumors of two members of the family carrying the p.A248G variant.
|
25381600 |
2015 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study analyzed TERT promoter mutations in various thyroid tumors and examined their relationship with clinicopathologic factors and the BRAF(V600E) mutation in PTC cases.
|
27184112 |
2016 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The CVF approach identified single-mutation driver candidates, such as BRAF V600E in the thyroid cancer dataset.
|
26543077 |
2016 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this work, we attempt to discuss some of the most recent molecular, preclinical and clinical evidence to construct a more exhaustive model of function for the BRAF V600E in development, progression and therapeutic approach of thyroid cancer.
|
24828987 |
2015 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
A literature search using PubMed identified all the pertinent literature on the identification and utilization of the B-Raf(V600E) mutation in thyroid cancer.
|
20637346 |
2010 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The diagnostic sensitivity for thyroid cancer is significantly increased by BRAF V600E mutation analysis, indicating that the screening for BRAF mutation in FNAB samples has a relevant diagnostic potential.
|
22535974 |
2012 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Testing of a patient's thyroid cancer for B-Raf(V600E) will yield important information about potential tumor aggressiveness and also allow for future use of targeted therapies with selective B-Raf(V600E) inhibitors, such as PLX4720.
|
20498063 |
2010 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We developed an allele-specific real-time PCR method for the detection of BRAF(T1799A) in blood samples and studied prospectively blood samples from 193 patients with thyroid cancer (173 PTC, 20 non-PTC) attending for routine follow-up.
|
19850689 |
2009 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, this study has confirmed that the BRAF(T1799A) mutation confers cancer cells sensitivity to PLX4032 and demonstrated its specific potential as an effective and BRAF(T1799A) mutation-selective therapeutic agent for thyroid cancer.
|
21185263 |
2011 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, this study on a large cohort of TC patients from Middle East demonstrates that TERT promoter mutations are relatively common, especially in the non-CPTC, and are associated with more aggressive histopathological features, BRAF(V600E) mutation, and disease persistence/recurrence than the WT TERT.
|
26354077 |
2015 |
Thyroid Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This represents a novel mechanism in BRAF V600E-promoted PTC aggressiveness and identifies WIPF1 as a novel therapeutic target for thyroid cancer.
|
27863429 |
2017 |